Novartis Faces Uphill Battle For Patent Extensions In Europe

Law360, New York (September 7, 2004, 12:00 AM EDT) -- In a blow to Novartis, an aide to the European Court of Justice has advised the court to oppose the Swiss drug maker’s attempts to extend patents for two drugs in the 28-nation European Economic Area (EEA).

The U.K. was correct to date the start of patent protection for transplant drug Simulect (basiliximab) and anti-malarial treatment Riamet on their approval in Liechtenstein, said Damaso Ruiz-Jarabo Colomer, an advocate general at the European Court of Justice in Luxembourg.

Liechtenstein had automatically recognized the Swiss approval because of...
To view the full article, register now.